Lynch syndrome caused by germline PMS2 mutations: Delineating the cancer risk

Journal of Clinical Oncology

Volumn 33, Issue 4, 2015, Pages 319-325

  Ten Broeke, Sanne W ^a,q   Brohet, Richard M ^c   Tops, Carli M ^a   Van Der Klift, Heleen M ^a   Velthuizen, Mary E ^d   Bernstein, Inge ^k,l   Munar, Gabriel Capellá ^m   Garcia, Encarna Gomez ^e   Hoogerbrugge, Nicoline ^f   Letteboer, Tom G W ^d   Menko, Fred H ^g   Lindblom, Annika ⁿ   Mensenkamp, Arjen R ^f   Moller, Pal ^o   Van Os, Theo A ^h   Rahner, Nils ^p   Redeker, Bert J W ^h   Sijmons, Rolf H ⁱ   Spruijt, Liesbeth ^f   Suerink, Manon ^a   Vos, Yvonne J ⁱ   Wagner, Anja ^j   Hes, Frederik J ^a   Vasen, Hans F ^a,b   Nielsen, Maartje ^a   Wijnen, Juul T ^a   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Foundation for the Detection of Hereditary Tumors   (Netherlands)

^c Department of Orthopaedic Surgery   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k AALBORG UNIVERSITY HOSPITAL   (Denmark)

^l HVIDOVRE HOSPITAL   (Denmark)

^m BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o OSLO UNIVERSITY HOSPITAL   (Norway)

^p HEINRICH HEINE UNIVERSITY   (Germany)

^q NONE   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN PMS2; ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; PMS2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ADULT; AGED; ASCERTAINMENT BIAS; BREAST CANCER; CANCER CENTER; CANCER RISK; COLORECTAL CANCER; CONFERENCE PAPER; ENDOMETRIUM CANCER; FEMALE; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE; HUMAN; INTESTINE CANCER; KIDNEY CANCER; KIDNEY PELVIS; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; SEGREGATION ANALYSIS; COHORT ANALYSIS; COLORECTAL TUMOR; ENDOMETRIUM TUMOR; FAMILY HEALTH; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; NUCLEOTIDE SEQUENCE; RISK FACTOR; VERY ELDERLY;

ADENOSINE TRIPHOSPHATASES; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FAMILY HEALTH; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84921896169     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.8088     Document Type: Conference Paper

References (39)

1. Barrow E, Hill J, Evans DG: Cancer risk in Lynch syndrome. Fam Cancer 12:229-240, 2013
2. Hampel H, Stephens JA, Pukkala E, et al: Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: Later age of onset. Gastroenterology 129:415-421, 2005
3. Stoffel E, Mukherjee B, Raymond VM, et al: Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 137:1621-1627, 2009
4. Dowty JG, Win AK, Buchanan DD, et al: Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 34:490-497, 2013
5. Baglietto L, Lindor NM, Dowty JG, et al: Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 102:193-201, 2010
6. Nicolaides NC, Papadopoulos N, Liu B, et al: Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371:75-80, 1994
7. Clendenning M, Hampel H, LaJeunesse J, et al: Long-range PCR facilitates the identification of PMS2-specific mutations. Hum Mutat 27:490-495, 2006
8. Vaughn CP, Robles J, Swensen JJ, et al: Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes. Hum Mutat 31:588-593, 2010
9. van der Klift HM, Tops CM, Bik EC, et al: Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients. Hum Mutat 31:578-587, 2010
10. Worthley DL, Walsh MD, Barker M, et al: Familial mutations in PMS2 can cause autosomal dominant hereditary nonpolyposis colorectal cancer. Gastroenterology 128:1431-1436, 2005
11. Hendriks YM, de Jong AE, Morreau H, et al: Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): A guide for clinicians. CA Cancer J Clin 56:213-225, 2006
12. Senter L, Clendenning M, Sotamaa K, et al: The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135: 419-428, 2008
13. Bonadona V, Bonaiti B, Olschwang S, et al: Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305:2304-2310, 2011
14. Johannesma PC, van der Klift HM, van Grieken NC, et al: Childhood brain tumours due to germline bi-allelic mismatch repair gene mutations. Clin Genet 80:243-255, 2011
15. Truninger K, Menigatti M, Luz J, et al: Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 128:1160-1171, 2005
16. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268, 2004
17. Bakry D, Aronson M, Durno C, et al: Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. Eur J Cancer 50:987-996, 2014
18. Herkert JC, Niessen RC, Olderode-Berends MJ, et al: Paediatric intestinal cancer and polyposis due to bi-allelic PMS2 mutations: Case series, review and follow-up guidelines. Eur J Cancer 47:965-982, 2011
19. Wimmer K, Kratz CP, Vasen HF, et al: Diagnostic criteria for constitutional mismatch repair deficiency syndrome: Suggestions of the European consortium "Care for CMMRD" (C4CMMRD). J Med Genet 51:355-365, 2014
20. Borrá s E, Pineda M, Cadiñanos J, et al: Refining the role of PMS2 in Lynch syndrome: Germline mutational analysis improved by comprehensive assessment of variants. J Med Genet 50:552-563, 2013
21. Brohet RM, Velthuizen ME, Hogervorst FB, et al: Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet 51:98-107, 2014
22. Antoniou AC, Goldgar DE, Andrieu N, et al: A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 29:1-11, 2005
23. Talseth-Palmer BA, Wijnen JT, Brenne IS, et al: Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. Int J Cancer 132:1556-1564, 2013
24. Wijnen JT, Brohet RM, van Eijk R, et al: Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. Gastroenterology 136:131-137, 2009
25. van Duijnhoven FJ, Botma A, Winkels R, et al: Do lifestyle factors influence colorectal cancer risk in Lynch syndrome? Fam Cancer 12:285-293, 2013
26. Pande M, Lynch PM, Hopper JL, et al: Smoking and colorectal cancer in Lynch syndrome: Results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. Clin Cancer Res 16:1331-1339, 2010
27. van Lier MG, Leenen CH, Wagner A, et al: Yield of routine molecular analyses in colorectal cancer patients - 70 years to detect underlying Lynch syndrome. J Pathol 226:764-774, 2012
28. Leenen CH, van Lier MG, van Doorn HC, et al: Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. Gynecol Oncol 125:414-420, 2012
29. Vasen HF, Watson P, Mecklin JP, et al: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453-1456, 1999
30. Dorschner MO, Amendola LM, Turner EH, et al: Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet 93: 631-640, 2013
31. Boone PM, Soens ZT, Campbell IM, et al: Incidental copy-number variants identified by routine genome testing in a clinical population. Genet Med 15:45-54, 2013
32. Castera L, Krieger S, Rousselin A, et al: Nextgeneration sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet [epub ahead of print on February 19, 2014]
33. Vasen HF, Möslein G, Alonso A, et al: Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44:353-362, 2007
34. Vasen HF, Blanco I, Aktan-Collan K, et al: Revised guidelines for the clinical management of Lynch syndrome (HNPCC): Recommendations by a group of European experts. Gut 62:812-823, 2013
35. Hendriks YM, Wagner A, Morreau H, et al: Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: Impact on counseling and surveillance. Gastroenterology 127:17-25, 2004
36. Ketabi Z, Gerdes AM, Mosgaard B, et al: The results of gynecologic surveillance in families with hereditary nonpolyposis colorectal cancer. Gynecol Oncol 133:526-530, 2014
37. PylvänäinenK, Lehtinen T, Kellokumpu I, et al: Causes of death of mutation carriers in Finnish Lynch syndrome families. Fam Cancer 11:467-471, 2012
38. Ketabi Z, Bartuma K, Bernstein I, et al: Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol 121:462-465, 2011
39. Bernstein IT, Myrhøj T: Surveillance for urinary tract cancer in Lynch syndrome. Fam Cancer 12: 279-284, 2013